GRP
BCRX icon

Global Retirement Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

Global Retirement Partners’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$700 Buy
+70
New +$633 ﹤0.01% 4242
2025
Q4 		$546 Buy
+70
New +$506 ﹤0.01% 3984

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Global Retirement Partners's BCRX Position: Q2 2026 in Review

Global Retirement Partners opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 70 shares worth $700. The stake represents ﹤0.01% of the portfolio and ranks #4242 among its holdings. This is a return to the name: Global Retirement Partners previously reported a position in BCRX as recently as Q4 2025.

Global Retirement Partners first reported a position in BCRX in Q4 2025 and has held it in 2 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Global Retirement Partners held 70 shares of BioCryst Pharmaceuticals worth $700 as of Q2 2026.
  • BioCryst Pharmaceuticals was a new Global Retirement Partners position in Q2 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Global Retirement Partners's portfolio in Q2 2026, its #4242 holding.
  • Global Retirement Partners first reported a position in BioCryst Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Global Retirement Partners's 13F filing for Q2 2026, filed 6 Aug 2026.